![]() | Jeffrey P CallenUniversity of Louisville School of Medicine, Louisville, Kentucky. | Division of Dermatology, University of Louisville, Louisville, Kentucky. | University of Louisville, ... |
KOL Resume for Jeffrey P Callen
Year | |
---|---|
2022 | University of Louisville School of Medicine, Louisville, Kentucky. |
2021 | University of Louisville, Division of Dermatology |
2020 | University of Louisville, Division of Dermatology, Department of Medicine, Louisville, KY, USA |
2019 | Division of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky. |
2018 | University of Louisville, Louisville, Kentucky Associate Editor, JAMA Dermatology |
2017 | Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky. Electronic address: |
2016 | Division of Dermatology, University of Louisville, Louisville, KY, USA |
2015 | Department of Medicine, Division of Dermatology, University of Louisville, 3810 Springhurst Blvd, 40241, Louisville, KY, USA |
2014 | Department of Medicine, Division of Dermatology, University of Louisville, Louisville, Kentucky |
2012 | Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Kentucky 40202, USA University of Louisville School of Medicine, 310 East Broadway, Louisville, KY 40202, U.S.A. |
2011 | Department of Pathology and Laboratory Medicine (Drs Hillesheim and Bahrami) and Division of Dermatology, Department of Medicine (Drs Bahrami, Jeffy, and Callen), University of Louisville, Louisville, Kentucky. University of Louisville School of Medicine, Division of Dermatology, Louisville, Kentucky, USA |
2010 | Division of Dermatology, University of Louisville, Louisville, Kentucky (Dr Callen). |
2009 | Division of Dermatology and Professor of Dermatology, Department of Dermatology, Yale University, New Haven CT, USA |
2008 | Division of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky, USA Departments of Dermatology (Drs Owen, Malone, and Callen) and Pathology (Dr Malone), University of Louisville, Louisville, Kentucky. |
2007 | Division of Dermatology, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA |
2006 | From the Division of Dermatology, University of Louisville |
2005 | Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA |
2004 | From the Division of Dermatology, Department of Medicine, University of Louisville School of Medicine USA Division of Dermatology, University of Louisville School of Medicine, Louisville, KY 40292, U.S.A. |
2003 | University of Louisville School of Medicine, Louisville, Kentucky, USA |
2002 | University of Louisville, School of Medicine, 310 East Broadway, KY 40202, USA. Department of Medicine, Division of Dermatology and |
2001 | Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA, US Denver, Colorado; Louisville, Kentucky; New York, New York; Doylestown, Pennsylvania; Boston, Massachusetts; Washington, DC; and San Francisco, California From the Women's Dermatologic Society |
2000 | The Division of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky Division of Dermatology, University of Louisville, 310 East Broadway, Suite 200, Louisville, KY 40202, USA |
1999 | From the Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Ky. Division of Dermatology, University of Louisville, School of Medicine, Louisville, Kentucky USA University of Louisville, Kentucky, U.S.A. |
Jeffrey P Callen: Influence Statistics
Concept | World rank |
---|---|
agents generally | #1 |
overhanging violaceous border | #1 |
hematologic disease malignancy | #1 |
resolution bullous eruption | #1 |
ace levels extent | #1 |
patients idiopathic dm | #1 |
article skin manifestations | #1 |
infiltrate theory | #1 |
reaction photosensitivity | #1 |
vasculitides dermatomyositis | #1 |
linear band iga | #1 |
skin instance | #1 |
colchicine reinstitution | #1 |
vancomycininduced labd | #1 |
discoid sunscreening agents | #1 |
mortality prompt | #1 |
13 methotrexate | #1 |
dapsone effective | #1 |
bullous dermatoses pemphigus | #1 |
common features disorders | #1 |
hypertrophy lupus | #1 |
quality extent severity | #1 |
case report rothmundthomson | #1 |
immunoglobulin deposit | #1 |
skin examination evaluation | #1 |
malignancy — | #1 |
neutrophilicpredominant type | #1 |
apg hematologic disease | #1 |
cell panniculitis | #1 |
erythematosus unique | #1 |
diagnosis glomeruloid | #1 |
discontinuation hydroxyurea therapy | #1 |
gangrenosum apg | #1 |
rare cutaneous manifestation | #1 |
lv azathioprine | #1 |
thyroiditis bullous | #1 |
minimal chlorambucil toxicity | #1 |
offlabel dermatologic diseases | #1 |
time 40 drugs | #1 |
office patient inclusion | #1 |
polymyositis members | #1 |
antimalarials lupus erythematosus | #1 |
immunomodulatory therapies hormones | #1 |
nondiscle | #1 |
refractory disease author | #1 |
oral dapsone therapy | #1 |
calcipotriene tacrolimus | #1 |
variations clinical morphology | #1 |
dermatomyositis reduction | #1 |
sweet syndrome vasculitis | #1 |
Open the FULL List in Excel | |
Prominent publications by Jeffrey P Callen
Autoantibodies in Lichen Planus Pemphigoides React with a Novel Epitope within the C-Terminal NC16A Domain of BP180
[ PUBLICATION ]
Lichen planus pemphigoides is an autoimmune subepidermal blistering disease. The finding of immunoglobulin G antibodies directed against the basement membrane zone differentiates it from bullous lichen planus. The aim of this study was to identify the target antigen of lichen planus pemphigoides autoantibodies. Sera from lichen planus pemphigoides patients (n = 4) stained the epidermal side of NaCl-split human skin in a pattern indistinguishable from that produced by bullous pemphigoid ...
Known for Planus Pemphigoides | Nc16a Domain | Bullous Pemphigoid | Autoimmune Response | Autoantibodies Lichen |
Successful treatment of lentigo maligna and lentigo maligna melanoma with mohs' micrographic surgery aided by rush permanent sections
[ PUBLICATION ]
BACKGROUND: Lentigo maligna (LM) is a pigmented neoplasm on sun-exposed skin of elderly patients. LM slowly increases in size and may become lentigo maligna melanoma (LMM), a potentially fatal malignancy. Complete excision is the treatment of choice. Mohs' micrographic surgery (MMS) with frozen and permanent sections may be used for complete eradication of the lesion, while sparing as much normal tissue as possible. The authors studied the efficacy of MMS for the treatment of LM and ...
Known for Permanent Sections | Lentigo Maligna Melanoma | Lm Lmm | Mms Treatment | Micrographic Surgery |
OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
METHODS: The classification criteria were derived from a set of 702 expert-rated patient scenarios. Recursive partitioning was used to derive an ...
Known for Classification Criteria | Lupus International | Sle Patient | Antinuclear Biopsy | Derivation Validation |
Objective To study the impact of obesity and smoking on psoriasis.Design Cross-sectional study.Setting University of Utah Department of Dermatology clinics.Patients A case series of patients with psoriasis enrolled in the prospective Utah Psoriasis Initiative (UPI) (which carefully performs phenotyping of patients with psoriasis) was compared with 3 population databases: the Behavioral Risk Factor Surveillance System of the Utah population, the 1998 patient-member survey from the ...
Known for Psoriasis Obesity | Clinical Severity | 18 Years | Hospital Based | Normal Weight |
Associations of Tumor Necrosis Factor α and HLA Polymorphisms with Adult Dermatomyositis: Implications for a Unique Pathogenesi 1
[ PUBLICATION ]
We recently reported that the -308A tumor necrosis factor alpha promoter polymorphism is associated with the photosensitive disorder subacute cutaneous lupus erythematosus and mediates an exaggerated tumor necrosis factor alpha response to ultraviolet B. We now sought to examine the association of this polymorphism with adult dermatomyositis, a photosensitive disease that exhibits some features in common with subacute cutaneous lupus erythematosus. Fifty adult patients with ...
Known for Necrosis Factor | Adult Dermatomyositis | Cutaneous Lupus Erythematosus | Genetic Promoter Regions | 308a Allele |
Mannose Binding Lectin (MBL) Polymorphisms Associated with Low MBL Production in Patients with Dermatomyositis 1
[ PUBLICATION ]
One theory for the pathophysiology of photosensitive autoimmune skin diseases is that photoinduction of tumor necrosis factor alpha (TNFalpha) secretion leads to keratinocyte apoptosis and translocation of previously sequestered cellular antigens that then activate the immune system. We previously found an association of the overproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythematosus. Here we focused on mannose binding lectin (MBL), ...
Known for Mannose Binding Lectin | Adult Dermatomyositis | Mbl Polymorphisms | Lupus Erythematosus | Apoptotic Cells |
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis
[ PUBLICATION ]
BACKGROUND: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed.
OBJECTIVE: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis.
METHODS: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a ...
Known for Plaque Psoriasis | Treatment Tazarotene | Daily Fluocinonide | 12 Weeks | 01 Gel |
The presence of the discoid lupus erythematosus (DLE) skin lesion in a patient with systemic lupus erythematosus (SLE) has been suggested to be a marker of less frequent and less severe renal disease. The clinical and laboratory features of seventeen patients who were seen in a dermatology practice and who had DLE as a manifestation of SLE (DLE-SLE) are reported. DLE preceded the diagnosis of SLE in eight patients. In six patients, the onset was concurrent, whereas in three the SLE was ...
Known for Systemic Lupus Erythematosus | Sle Patients | Renal Disease | Cutaneous Lesions | Raynauds Phenomenon |
OBJECTIVE: To prepare a dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012) to address vasculitides affecting the skin (D-CHCC). The goal was to standardize the names and definitions for cutaneous vasculitis.
METHODS: A nominal group technique with a facilitator was used to reach consensus on the D-CHCC nomenclature, using multiple face-to-face meetings, e-mail discussions, and teleconferences.
RESULTS: ...
Known for Cutaneous Vasculitis | Vascular Terminology | Systemic Vasculitides | Differential Humans | Skin Skin Diseases |
SUMMARY Skin disease in patients with lupus erythematosus may be subdivided into two broad categories - those lesions that when biopsied demonstrate interface dermatitis and those that do not demonstrate interface dermatitis. The skin lesions that are represented by the interface dermatitis include discoid lupus erythematosus, subacute cutaneous lupus erythematosus and acute cutaneous lupus erythematosus. Patients with these 'specific' manifestations have varying degrees of systemic ...
Known for Lupus Erythematosus | Interface Dermatitis | Systemic Disease | Skin Lesions | Patients Cutaneous |
BACKGROUND: The cutaneous manifestations of dermatomyositis can be the most prominent finding and are often difficult to treat.
OBJECTIVE: Our purpose was to determine whether low-dose methotrexate administered weekly in combination with other systemic therapies or as a sole systemic agent is effective in the treatment of the cutaneous disease in patients with dermatomyositis.
METHODS: We reviewed the records of 13 patients who received oral methotrexate in doses ranging from 2.5 to 30 ...
Known for Cutaneous Manifestations | Patients Dermatomyositis | Dose Methotrexate | Effective Corticosteroid | Skin Lesions |
Pyoderma gangrenosum (PG) is an idiopathic, inflammatory, ulcerative disease of undetermined cause. The diagnosis is based on clinical and pathologic features and requires exclusion of conditions that produce ulcerations. An atypical bullous variant (atypical pyoderma gangrenosum, APG) exists with clinical features similar to those of Sweet syndrome. Because PG is a rare disease, few large case series have been reported. Pyoderma gangrenosum was first recognized as a unique disease ...
Known for Pyoderma Gangrenosum | Patients Pg | Case Review | Child Child | Sweet Syndrome |
The term peripheral ulcerative keratitis represents a spectrum of inflammatory diseases, characterized by cellular infiltration, corneal thinning, and ulceration. Neutrophilic dermatoses are rarely associated with peripheral ulcerative keratitis. To date, peripheral ulcerative keratitis has only been reported in patients with pyoderma gangrenosum. Separate episodes of pyoderma gangrenosum, Sweet's syndrome, and pustular vasculitis developed in a 60-year-old patient with rheumatoid ...
Known for Peripheral Ulcerative Keratitis | Rheumatoid Arthritis | Pyoderma Gangrenosum | Sweet Syndrome | Neutrophilic Dermatoses |
Key People For Pyoderma Gangrenosum
Jeffrey P Callen:Expert Impact
Concepts for whichJeffrey P Callenhas direct influence:Pyoderma gangrenosum, Lupus erythematosus, Cutaneous lupus erythematosus, Cutaneous lupus, Scalp involvement, Systemic disease, Cutaneous vasculitis, Mycophenolate mofetil.
Jeffrey P Callen:KOL impact
Concepts related to the work of other authors for whichfor which Jeffrey P Callen has influence:Systemic lupus erythematosus, Pyoderma gangrenosum, Lupus nephritis, Sle patients, Actinic keratosis, Rheumatoid arthritis, Atopic dermatitis.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |